dissecting the stealthy gut colonization of the human pathogen klebsiella pneumoniae.

  • Funded by UK Research and Innovation (UKRI)
  • Total publications:9 publications

Grant number: 437

Grant search

Key facts

  • Disease

    Bacterial infection caused by Klebsiella pneumonia
  • Start & end year

    2025.0
    2030.0
  • Known Financial Commitments (USD)

    $2,806,422.28
  • Funder

    UK Research and Innovation (UKRI)
  • Principal Investigator

    .
  • Research Location

    United Kingdom
  • Lead Research Institution

    London School of Hygiene & Tropical Medicine
  • Research Priority Alignment

    N/A
  • Research Category

    Pathogen: natural history, transmission and diagnostics

  • Research Subcategory

    Pathogen morphology, shedding & natural history

  • Special Interest Tags

    N/A

  • Study Type

    Non-Clinical

  • Clinical Trial Details

    N/A

  • Broad Policy Alignment

    Pending

  • Age Group

    Not Applicable

  • Vulnerable Population

    Not applicable

  • Occupations of Interest

    Not applicable

Abstract

Your gut houses a bustling community of trillions of microbes, mostly bacteria, containing more genes than the human genome. These microbes are involved in functions crucial to your health. These bacteria help to digest the food you eat, and they help with absorbing and synthesizing nutrients too. Gut microbes are involved in many other important processes including your body weight, your defense against infections, as well as your brain functions and they may even alleviate your anxiety. Not surprisingly, there is intensive research to find ways to improve our health by controlling and manipulating the resident microbes of the gut. Unfortunately, recent research has shown that our gut may also house other microbes, hidden, that cause infections when disseminate from the gut to other tissues. In fact, a number of studies interrogating patients admitted to the hospital that later develop infections in the blood have clearly established that the patients were the carriers in their guts in an asymptomatic way of the microbe causing the infection. Klebsiella pneumoniae is one of these microbes with the ability to co-exist peacefully in our gut but with also the ability to become a deadly microbe if reaching our tissues such as the lung or the blood. Klebsiella has been singled out as an urgent threat to human health by the UK Government, the U.S. Centers for Disease Control and Prevention, and the World Health Organization due to extremely antibiotic resistant strains. The increasing isolation of strains resistant to "last resort" antibiotics has significantly narrowed, or in some settings completely removed, the therapeutic options. This is particularly alarming in low and middle countries. This research is designed to unveil the incognito lifestyle of Klebsiella in our gut and to establish how Klebsiella can cross the gut to reach other tissues. We will characterize the gut environment promoting Klebsiella colonization and which one is hostile. Particularly, we will identify which of the microbes of our gut are able to out-compete Klebsiella and which ones favour Klebsiella colonization. Lastly, we will define which of the small genetic variations that difference each of us render our gut permissive for Klebsiella colonization, and which ones are restrictive. The findings of this research shall be the foundation of innovative therapeutics to prevent the gut colonization of Klebsiella. These new therapies may involve boosting our gut defenses to generate a harsh environment for Klebsiella, the use of rational design probiotics that include gut microbes efficient eliminating Klebsiella, and antibodies-based treatments or vaccines targeting Klebsiella.

Publicationslinked via Europe PMC

Last Updated:15 hours ago

View all publications at Europe PMC

<i>Trans</i>-cinnamaldehyde fumigation inhibits <i>Escherichia coli</i> by affecting the mechanism of intracellular biological macromolecules.

Development of PLGA Nanoparticles with a Glycosylated Myelin Oligodendrocyte Glycoprotein Epitope (MOG35-55) against Experimental Autoimmune Encephalomyelitis (EAE).

Validation of HER2 Status in Whole Genome Sequencing Data of Breast Cancers with the Ploidy-Corrected Copy Number Approach.

Epigenetic SMAD3 Repression in Tumor-Associated Fibroblasts Impairs Fibrosis and Response to the Antifibrotic Drug Nintedanib in Lung Squamous Cell Carcinoma.

Evaluating adhesion and alignment of dental pulp stem cells to a spider silk substrate for tissue engineering applications.

Characterization of NoV P particle-based chimeric protein vaccines developed from two different expression systems.

In silico designing, cloning, and heterologous expression of novel chimeric human B lymphocyte CD20 extra loop.

Effects of gemfibrozil on the oxygen transport properties of erythrocytes.